RP 593

Drug Profile

RP 593

Alternative Names: (Tc(99))RP593; 99mTc-c(RGDfK*)2HYNIC

Latest Information Update: 12 Sep 2003

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Cyclic peptides; Organotechnetium compounds; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 29 May 2001 Preclinical development for Cancer diagnosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top